News Image

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

Provided By GlobeNewswire

Last update: Jun 10, 2024

SZN-043 is a novel biotherapeutic shown to potentiate Wnt signaling and induce proliferation of hepatocytes in preclinical models

Treatment with SZN-043 in the Phase 1a trial was safe and well tolerated in healthy volunteers and patients with a history of liver cirrhosis

Read more at globenewswire.com

SURROZEN INC

NASDAQ:SRZN (10/20/2025, 8:17:18 PM)

After market: 13.95 +0.16 (+1.16%)

13.79

+0.21 (+1.55%)



Find more stocks in the Stock Screener

Follow ChartMill for more